BACKGROUND: Although genetic variants in MYH7 are the most frequent cause of pediatric genetic dilated cardiomyopathy (DCM), there are no studies available describing this entity. We sought to describe clinical features, analyze variant location, and explore predictors of bad prognosis in pediatric MYH7-related DCM. METHODS AND RESULTS: We evaluated clinical records from 44 patients (24 men; median age at diagnosis, 0.54 [interquartile range, 0.01–10.8] years) with pathogenic/likely pathogenic variants in MYH7 diagnosed with DCM at pediatric age (<18 years) followed at 13 international centers. We also explored risk factors associated with a composite end point of end-stage heart failure defined as heart transplantation or heart failure–related death. Twenty-two patients (50%) were diagnosed at age <6 months, including 7 (16%) at birth. Left ventricular (LV) hypertrabeculation features were present in 15 (38%), particularly among patients with genetic variants in the head domain. After a median follow-up of 6.1 years (interquartile range, 1.9–13.4), 15 patients (36%) required a heart transplant (n=14) or died due to end-stage heart failure (n=1), 15 patients (36%) persisted with systolic dysfunction despite treatment, 12 (29%) had a significant increase in LV ejection fraction, and 2 were lost to follow-up. Overall, end-stage heart failure event rate was 25% at 5 years. New York Heart Association class III to IV (hazard ratio [HR], 7.67 [95% CI, 2.16–27.2]; P=0.002) and LV ejection fraction ≤35% (HR, 4.00 [95% CI, 1.11–14.4]; P=0.03) were the best predictors of bad prognosis. CONCLUSIONS: Pediatric MYH7-related DCM is characterized by early onset, frequent LV hypertrabeculation, and poor prognosis. Advanced New York Heart Association class and low LV ejection fraction emerged as predictors of end-stage heart failure.

Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy / de Frutos, Fernando; Phd, Md; Pablo Ochoa, Juan; Phd, Md; Webster, Gregory; Mph, Md; Jansen, Mark; Phd, Md; Md, Paloma Remior; Rasmussen, Torsten B.; Phd, Md; Phd, Maria Sabater-Molina; Barriales-Villa, Roberto; Phd, Md; Phd, Francesca Girolami; Md, Sergi Cesar; Md, M. Eugenia Fuentes-Cañamero; Md, Reyes Alvarez García-Rovés; Md, Karim Wahbi; Limeres, Javier; Phd, Md; Kubanek, Milos; Phd, Md; MD PhD, Martijn G. Slieker; Sarquella-Brugada, Georgia; Phd, Md; Abrams, Dominic J.; Md, Mbbs; Mba, ; Phd, Dennis Dooijes; Domínguez, Fernando; Phd, Md; Garcia-Pavia, Pablo; Phd, Md; Md, for the European Genetic Cardiomyopathies Initiative Investigators (Eva Cabrera-Romero; Md, Marta Cobo-Marcos; Md, Luis Escobar-Lopez; Domínguez, Fernando; Phd, Md; González-López, Esther; Phd, Md; Peiro-Aventin, Belen; Md, ; Md, Nerea Mora-Ayestarán; Krebsova, Alice; Phd, Md; Piherova, Lenka; Phd, Msc; MD PhD, Annette F Baas; Khraiche, Diala; EL HACHMI, Mohamed; Md, Jose María Larrañaga-Moreira; Md, Fernando Rueda Núñez; Md, Esteban Martin Álvarez; Md, Silvia Favilli; Centeno Jiménez, Miriam; Phd, Constancio Medrano López. MD; Md, Irene Méndez Fernández.; Md, Silvia Vilches Soria.; Md, Cristina Gómez González.; Phd, Ana Isabel Fernández Ávila. MD; Phd, María Angeles Espinosa Castro. MD; MD. ), Jesper V. Bjerre. - In: JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE. - ISSN 2047-9980. - (2024).

Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy

Mohamed El hachmi
Investigation
;
2024

Abstract

BACKGROUND: Although genetic variants in MYH7 are the most frequent cause of pediatric genetic dilated cardiomyopathy (DCM), there are no studies available describing this entity. We sought to describe clinical features, analyze variant location, and explore predictors of bad prognosis in pediatric MYH7-related DCM. METHODS AND RESULTS: We evaluated clinical records from 44 patients (24 men; median age at diagnosis, 0.54 [interquartile range, 0.01–10.8] years) with pathogenic/likely pathogenic variants in MYH7 diagnosed with DCM at pediatric age (<18 years) followed at 13 international centers. We also explored risk factors associated with a composite end point of end-stage heart failure defined as heart transplantation or heart failure–related death. Twenty-two patients (50%) were diagnosed at age <6 months, including 7 (16%) at birth. Left ventricular (LV) hypertrabeculation features were present in 15 (38%), particularly among patients with genetic variants in the head domain. After a median follow-up of 6.1 years (interquartile range, 1.9–13.4), 15 patients (36%) required a heart transplant (n=14) or died due to end-stage heart failure (n=1), 15 patients (36%) persisted with systolic dysfunction despite treatment, 12 (29%) had a significant increase in LV ejection fraction, and 2 were lost to follow-up. Overall, end-stage heart failure event rate was 25% at 5 years. New York Heart Association class III to IV (hazard ratio [HR], 7.67 [95% CI, 2.16–27.2]; P=0.002) and LV ejection fraction ≤35% (HR, 4.00 [95% CI, 1.11–14.4]; P=0.03) were the best predictors of bad prognosis. CONCLUSIONS: Pediatric MYH7-related DCM is characterized by early onset, frequent LV hypertrabeculation, and poor prognosis. Advanced New York Heart Association class and low LV ejection fraction emerged as predictors of end-stage heart failure.
2024
dilated cardiomyopathy ;genetics ;MYH7 ;pediatric
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy / de Frutos, Fernando; Phd, Md; Pablo Ochoa, Juan; Phd, Md; Webster, Gregory; Mph, Md; Jansen, Mark; Phd, Md; Md, Paloma Remior; Rasmussen, Torsten B.; Phd, Md; Phd, Maria Sabater-Molina; Barriales-Villa, Roberto; Phd, Md; Phd, Francesca Girolami; Md, Sergi Cesar; Md, M. Eugenia Fuentes-Cañamero; Md, Reyes Alvarez García-Rovés; Md, Karim Wahbi; Limeres, Javier; Phd, Md; Kubanek, Milos; Phd, Md; MD PhD, Martijn G. Slieker; Sarquella-Brugada, Georgia; Phd, Md; Abrams, Dominic J.; Md, Mbbs; Mba, ; Phd, Dennis Dooijes; Domínguez, Fernando; Phd, Md; Garcia-Pavia, Pablo; Phd, Md; Md, for the European Genetic Cardiomyopathies Initiative Investigators (Eva Cabrera-Romero; Md, Marta Cobo-Marcos; Md, Luis Escobar-Lopez; Domínguez, Fernando; Phd, Md; González-López, Esther; Phd, Md; Peiro-Aventin, Belen; Md, ; Md, Nerea Mora-Ayestarán; Krebsova, Alice; Phd, Md; Piherova, Lenka; Phd, Msc; MD PhD, Annette F Baas; Khraiche, Diala; EL HACHMI, Mohamed; Md, Jose María Larrañaga-Moreira; Md, Fernando Rueda Núñez; Md, Esteban Martin Álvarez; Md, Silvia Favilli; Centeno Jiménez, Miriam; Phd, Constancio Medrano López. MD; Md, Irene Méndez Fernández.; Md, Silvia Vilches Soria.; Md, Cristina Gómez González.; Phd, Ana Isabel Fernández Ávila. MD; Phd, María Angeles Espinosa Castro. MD; MD. ), Jesper V. Bjerre. - In: JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE. - ISSN 2047-9980. - (2024).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1725558
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact